Added Value of 18 FDG Pet-scanner in Diagnosis and Management of Subclinical Rejection in Kidney Transplant Patients
Launched by UNIVERSITY OF LIEGE · Jan 6, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to diagnose and manage kidney transplant rejection, specifically focusing on "subclinical" rejection, which means rejection that happens without obvious symptoms. Currently, doctors use a procedure called renal biopsy to check for this type of rejection, but it can be invasive and carries risks. Researchers are exploring the use of a special imaging technique called 18FDG PET/CT to help determine whether a biopsy is necessary and to guide decisions about reducing or stopping corticosteroid medications, which have known side effects.
To participate, individuals must be over 18 years old and have received a kidney transplant. However, pregnant women and certain patients with specific complications are not eligible. Participants will undergo the PET/CT scan alongside the routine biopsy at three months after their transplant. Depending on the results of both tests, the doctors will decide how to proceed with their treatment. This study aims to improve the care of kidney transplant patients by reducing unnecessary procedures and helping manage medications more effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Kidney recipients aged over 18 and of all sexes
- Exclusion Criteria:
- • Pregnant patients
- • Polyomavirus nephropathy
- • Highly sensitised patients (historical or at 3 months Donor specific antibodies)
- • No corticosteroids withdrawal allowed (second kidney transplantation or primary disease)
About University Of Liege
The University of Liège, a prestigious research institution in Belgium, is committed to advancing medical science through innovative clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive expertise in various fields, including medicine, pharmacology, and biomedical engineering, to conduct high-quality research aimed at improving patient outcomes. The institution fosters a rigorous ethical framework and adheres to international standards in clinical research, ensuring the integrity and reliability of its studies. Through its clinical trials, the University of Liège aims to contribute significantly to the development of novel therapeutic approaches and enhance the understanding of complex health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Liege, Liège, Belgium
Liege, , Belgium
Patients applied
Trial Officials
Francois Jouret
Principal Investigator
University of Liege
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials